2viq

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (10:46, 7 July 2021) (edit) (undo)
 
(9 intermediate revisions not shown.)
Line 1: Line 1:
-
{{Seed}}
 
-
[[Image:2viq.png|left|200px]]
 
-
<!--
+
==Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator==
-
The line below this paragraph, containing "STRUCTURE_2viq", creates the "Structure Box" on the page.
+
<StructureSection load='2viq' size='340' side='right'caption='[[2viq]], [[Resolution|resolution]] 2.00&Aring;' scene=''>
-
You may change the PDB parameter (which sets the PDB file loaded into the applet)
+
== Structural highlights ==
-
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+
<table><tr><td colspan='2'>[[2viq]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2VIQ FirstGlance]. <br>
-
or leave the SCENE parameter empty for the default display.
+
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=D55:4-(2-AMINOETHOXY)-N-(2,5-DIETHOXYPHENYL)-3,5-DIMETHYLBENZAMIDE'>D55</scene></td></tr>
-
-->
+
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1c5w|1c5w]], [[1c5x|1c5x]], [[1c5y|1c5y]], [[1c5z|1c5z]], [[1ejn|1ejn]], [[1fv9|1fv9]], [[1gi7|1gi7]], [[1gi9|1gi9]], [[1gj7|1gj7]], [[1gj8|1gj8]], [[1gj9|1gj9]], [[1gjc|1gjc]], [[1kdu|1kdu]], [[1o5c|1o5c]], [[1owd|1owd]], [[1owh|1owh]], [[1owj|1owj]], [[1sc8|1sc8]], [[1f5l|1f5l]], [[1f92|1f92]], [[1gi8|1gi8]], [[1gja|1gja]], [[1gjb|1gjb]], [[1gjd|1gjd]], [[1lmw|1lmw]], [[1o3p|1o3p]], [[1o5a|1o5a]], [[1o5b|1o5b]], [[1owe|1owe]], [[1owi|1owi]], [[1owk|1owk]], [[1sqa|1sqa]], [[1sqo|1sqo]], [[1sqt|1sqt]], [[1u6q|1u6q]], [[1vj9|1vj9]], [[1w0z|1w0z]], [[1w10|1w10]], [[1w12|1w12]], [[1w14|1w14]], [[1vja|1vja]], [[1w11|1w11]], [[1w13|1w13]], [[2jde|2jde]], [[2vin|2vin]], [[2vio|2vio]], [[2vip|2vip]], [[2viv|2viv]], [[2viw|2viw]]</div></td></tr>
-
{{STRUCTURE_2viq| PDB=2viq | SCENE= }}
+
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2viq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2viq OCA], [https://pdbe.org/2viq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2viq RCSB], [https://www.ebi.ac.uk/pdbsum/2viq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2viq ProSAT]</span></td></tr>
 +
</table>
 +
== Disease ==
 +
[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
 +
== Function ==
 +
[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
 +
== Evolutionary Conservation ==
 +
[[Image:Consurf_key_small.gif|200px|right]]
 +
Check<jmol>
 +
<jmolCheckbox>
 +
<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/vi/2viq_consurf.spt"</scriptWhenChecked>
 +
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
 +
<text>to colour the structure by Evolutionary Conservation</text>
 +
</jmolCheckbox>
 +
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2viq ConSurf].
 +
<div style="clear:both"></div>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
-
===FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR===
+
Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.,Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M, Wallis NG J Med Chem. 2008 Jan 24;51(2):183-6. Epub 2007 Dec 29. PMID:18163548<ref>PMID:18163548</ref>
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 2viq" style="background-color:#fffaf0;"></div>
-
<!--
+
==See Also==
-
The line below this paragraph, {{ABSTRACT_PUBMED_18163548}}, adds the Publication Abstract to the page
+
*[[Urokinase 3D Structures|Urokinase 3D Structures]]
-
(as it appears on PubMed at http://www.pubmed.gov), where 18163548 is the PubMed ID number.
+
== References ==
-
-->
+
<references/>
-
{{ABSTRACT_PUBMED_18163548}}
+
__TOC__
-
 
+
</StructureSection>
-
==About this Structure==
+
[[Category: Human]]
-
2VIQ is a 1 chain structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2VIQ OCA].
+
[[Category: Large Structures]]
-
 
+
-
==Reference==
+
-
<ref group="xtra">PMID:18163548</ref><references group="xtra"/>
+
-
[[Category: Homo sapiens]]
+
[[Category: U-plasminogen activator]]
[[Category: U-plasminogen activator]]
-
[[Category: Callaghan, O.]]
+
[[Category: Callaghan, O]]
-
[[Category: Chessari, G.]]
+
[[Category: Chessari, G]]
-
[[Category: Congreve, M.]]
+
[[Category: Congreve, M]]
-
[[Category: Cowan, S R.]]
+
[[Category: Cowan, S R]]
-
[[Category: Frederickson, M.]]
+
[[Category: Frederickson, M]]
-
[[Category: Matthews, J E.]]
+
[[Category: Matthews, J E]]
-
[[Category: Mcmenamin, R.]]
+
[[Category: McMenamin, R]]
-
[[Category: Smith, D.]]
+
[[Category: Smith, D]]
-
[[Category: Vinkovic, M.]]
+
[[Category: Vinkovic, M]]
-
[[Category: Wallis, N G.]]
+
[[Category: Wallis, N G]]
[[Category: Blood coagulation]]
[[Category: Blood coagulation]]
[[Category: Egf-like domain]]
[[Category: Egf-like domain]]
Line 52: Line 68:
[[Category: Urokinase-type plasminogen activator]]
[[Category: Urokinase-type plasminogen activator]]
[[Category: Zymogen]]
[[Category: Zymogen]]
- 
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Feb 17 12:34:05 2009''
 

Current revision

Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

PDB ID 2viq

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools